Ueda Shuji, Kubo Masahiko, Matsuura Noriko, Matsunaga Hitomi, Kataoka Seiko, Maeda Tetsuo, Inui Yoshiaki, Kawata Sumio, Kanakura Yuzuru
Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Japan.
Intern Med. 2013;52(11):1235-8. doi: 10.2169/internalmedicine.52.0001.
Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma characterized by a high level of plasma cells circulating in the peripheral blood. The prognosis of PCL patients treated with conventional chemotherapy remains poor. Some reports have suggested that both bortezomib and lenalidomide are effective in treating PCL. We herein report a case of primary PCL in which the patient achieved stringent complete remission after receiving combination chemotherapy with reduced-dose bortezomib, lenalidomide and dexamethasone (VRd). This regimen was very effective, and no severe adverse events were observed. A reduced-dose VRd regimen can be considered in PCL patients.
浆细胞白血病（PCL）是多发性骨髓瘤的一种侵袭性变异型，其特征是外周血中循环的浆细胞水平较高。接受传统化疗的PCL患者预后仍然很差。一些报告表明，硼替佐米和来那度胺在治疗PCL方面均有效。我们在此报告一例原发性PCL病例，该患者在接受低剂量硼替佐米、来那度胺和地塞米松（VRd）联合化疗后实现了严格完全缓解。该方案非常有效，且未观察到严重不良事件。PCL患者可考虑采用低剂量VRd方案。
